Literature DB >> 2972671

Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice.

H R Chang1, F C Rudareanu, J C Pechère.   

Abstract

The activity of A-56268 (TE-031), a new macrolide, was tested in a murine model of acute toxoplasmosis. All control animals died in 8 +/- 1 days, while all mice treated with nine daily doses of A-56268 at 300 mg/kg, administered by gavage, survived. Moreover, 41.6% of the surviving mice were free from cerebral infection with Toxoplasma gondii, as assessed by brain subpassage. A-56268 is active against T. gondii in vivo, but further studies are needed to determine its usefulness in the treatment of human toxoplasmosis.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2972671     DOI： 10.1093/jac/22.3.359

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  10 in total

1.  Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

Authors:  S K Moshkani; A Dalimi
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

Review 2.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Clarithromycin therapy of experimental Treponema pallidum infections in hamsters.

Authors:  J Alder; K Jarvis; M Mitten; N L Shipkowitz; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

5.  In vitro and in vivo effects of doxycycline on Toxoplasma gondii.

Authors:  H R Chang; R Comte; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Localization of azithromycin in Toxoplasma gondii-infected cells.

Authors:  J C Schwab; Y Cao; M R Slowik; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis.

Authors:  F G Araujo; P Prokocimer; T Lin; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

8.  Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis.

Authors:  F Derouin; B Caroff; F Chau; P Prokocimer; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

9.  Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.

Authors:  H R Chang; D Arsenijevic; R Comte; A Polak; R L Then; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

10.  Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS.

Authors:  J Fernandez-Martin; C Leport; P Morlat; M C Meyohas; J P Chauvin; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.